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Abstract
Background: Tenofovir (TFV) gel is being evaluated as a microbicide with pericoital and daily regimens. To inhibit viral
replication locally, an adequate concentration in the genital tract is critical.
Methods and Findings: Forty-nine participants entered a two-phase study: single-dose (SD) and multi-dose (MD), were
randomized to collection of genital tract samples (endocervical cells [ECC], cervicovaginal aspirate and vaginal biopsies) at
one of seven time points [0.5, 1, 2, 4, 6, 8, or 24 hr(s)] post-dose following SD exposure of 4 mL 1% TFV gel and received a
single dose. Forty-seven were randomized to once (QD) or twice daily (BID) dosing for 2 weeks and to collection of genital
tract samples at 4, 8 or 24 hrs after the final dose, but two discontinued prior to gel application. Blood was collected during
both phases at the seven times post-dose. TFV exposure was low in blood plasma for SD and MD; median Cmax was 4.0 and
3.4 ng/mL, respectively (C#29 ng/mL). TFV concentrations were high in aspirates and tissue after SD and MD, ranging from
1.26104 to 9.96106 ng/mL and 2.16102 to 1.46106 ng/mL, respectively, and did not noticeably differ between proximal
and distal tissue. TFV diphosphate (TFV-DP), the intracellular active metabolite, was high in ECC, ranging from 7.16103 to
8.86106 ng/mL. TFV-DP was detectable in approximately 40% of the tissue samples, ranging from 1.86102 to 3.56104 ng/
mL. AUC for tissue TFV-DP was two logs higher after MD compared to SD, with no noticeable differences when comparing
QD and BID.
Conclusions: Single-dose and multiple-dose TFV gel exposure resulted in high genital tract concentrations for at least
24 hours post-dose with minimal systemic absorption. These results support further study of TFV gel for HIV prevention.
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Introduction
An estimated 25 million people have died from complications
from HIV since AIDS was recognized in 1981. Approximately 33
million people were living with HIV at the end of 2009 [1]. To
date, the only available strategies for female users for prevention of
sexual transmission are condoms and abstinence. New prevention
methods such as user-controlled topical microbicides that can be
applied to the vagina (or rectum) are urgently needed.
Tenofovir (TFV) is a nucleotide reverse transcriptase inhibitor
(NtRTI) that prevents transcription of HIV RNA to DNA when
converted to its active form, TFV diphosphate (TFV-DP) [2]. TFV
disoproxil fumarate (TDF, or VireadH), an orally bioavailable form
of TFV, received marketing approval for the treatment of HIV-1
infection in the United States in 2001. The cumulative worldwide
patient exposure to TDF is estimated to be 3.5 million patient-
years of treatment. In December 2006, Gilead granted co-
exclusive rights to CONRAD and the International Partnership
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for Microbicides (IPM) to develop, manufacture and distribute
TFV gel as a topical microbicide in resource-limited countries.
Multiple nonclinical studies have demonstrated the in vitro
efficacy of TFV for preventing HIV transmission [3]. TFV gel has
also been proven effective in preventing vaginal SHIV transmis-
sion in macaques [4]. TFV 1% gel has been found to be safe and
well tolerated in women and men [5–7]. Subsequent to this
current study, a randomized, double-blind, placebo-controlled
trial demonstrated that vaginal TFV 1% gel reduced male-to-
female HIV transmission by 39% [8]. In that study, women
followed a regimen in which dosing could take place up to
12 hours before and up to 12 hours after intercourse, with no
more than two doses administered in a 24-hour period. The HIV
incidence rates in the TFV gel and placebo arms were 5.6
(confidence interval [CI]: 4.0, 7.7) and 9.1 (CI: 6.9, 11.7) per 100
women-years, respectively (incidence rate ratio = 0.61; P=0.017).
Several other safety and effectiveness studies of 1% TFV gel as an
HIV prevention strategy are ongoing or in development, including
a daily dosing strategy (VOICE: clinicaltrials.gov NCT00705679).
The objectives of the pharmacokinetic (PK) study described
here were to assess the local and systemic exposure of extracellular
TFV and intracellular TFV-DP after a single dose and after 14
days of once- or twice-daily dosing. To our knowledge, this study
was the first to measure TFV and intracellular TFV-DP in human
genital tract cells and tissues.
Methods
The protocol for this trial and supporting CONSORT checklist
are available as supporting information; see Checklist S1 and
Protocol S1.
Ethics Statement
This study conformed to the principles of the Declaration of
Helsinki. The participants took part voluntarily and signed
informed consent forms. The study was reviewed and approved
by the PROFAMILA Ethics Committee, Santo Domingo,
Dominican Republic; the University of Pittsburgh Institutional
Review Board (IRB), Pittsburgh, PA; and the Western IRB,
Olympia, WA.
This pharmacokinetic study was performed at three centers:
PROFAMILIA in Santo Domingo, Dominican Republic; Magee-
Womens Hospital in Pittsburgh, PA; and Advances in Health in
Houston, TX. A total of 49 women at these three sites were
enrolled to receive a single vaginal dose (4 mL) of 1% TFV gel
followed by a 1-month wash-out period and then 2 weeks of either
once- or twice-daily dosing. A subset of participants in Pittsburgh
who completed the first two phases of the study was asked to
participate in a third phase with sample collection at 12 hours
after an additional single dose following a wash-out period.
Gels were packaged in labeled single use tubes of 1% TFV gel
and were inserted with a single-use applicator (HTI Plastics,
Lincoln, NE) administering 4 mL. Two different multiple-dose kits
were provided for once-daily (14 tubes and applicators) and twice-
daily (27 tubes and applicators) dosing over 14 days.
Healthy female volunteers 18–45 years old at low risk for
sexually transmitted infections were considered for enrollment.
Eligible volunteers had no clinically significant systemic diseases,
had regular menstrual cycles, were not at risk for pregnancy (using
ParagardH IUD, an effective barrier method, female sterilization
or abstinence, or had a vasectomized partner), agreed to be
sexually abstinent for 72 hours prior to, and for the entirety of, the
study phases, and provided signed informed consent.
Volunteers were ineligible if they were breastfeeding or within 2
months of their last pregnancy outcome, used any hormonal
contraceptives within 30 days of enrollment, used Depo-Provera
within 120 days of enrollment, had a history of an abnormal Pap
smear that had not been evaluated and treated as indicated, had a
recent history of drug or alcohol abuse, or used antiretroviral
therapies or drugs on a daily basis that could reduce renal or liver
function. Volunteers who tested positive for HIV, HBsAg,
Trichomonas vaginalis, Neisseria gonorrhoeae or Chlamydia trachomatis, or
had genital findings suspicious for a sexually transmitted infection
or a current vaginal or urinary tract infection were also ineligible
along with volunteers who had abnormal laboratory values or had
participated in another research study within 30 days of screening.
Participants were compensated for expenses incurred and time
and effort consistent with the region. This was reviewed and
approved by the local IRB based on their assessment that payment
would not influence the volunteer’s decision to participate in the
study.
Study Procedures
Each female volunteer participated in six visits over three
menstrual cycles, received gynecological examinations and was
tested for pregnancy at every visit. Figure 1 details the study
procedures. At screening, volunteers were given information about
the study and provided written informed consent. Baseline serum
biochemistries and complete blood counts were collected, and
testing for genital infections was performed. The enrollment visit
was scheduled on menstrual cycle day 19–24. Eligible volunteers
were enrolled and randomized to collection of endocervical cells
(ECC), cervicovaginal aspirate and vaginal biopsies at one of seven
time points [0.5, 1, 2, 4, 6, 8, and 24 hour(s)] post-dose for
measurement of TFV concentration. A single dose of intravaginal
TFV gel was applied at the study site. Blood samples were
collected at all seven time points to assess systemic TFV exposure.
Participants returned for a 2-week course of intravaginal TFV
gel after at least a 1-month wash-out and after menstrual flow
ceased. Participants were randomly assigned to either once-daily
(in the morning) or twice-daily (at 12-hour intervals) gel
application and received study supplies to use at home.
Participants returned for an interim visit after 1 week and a final
treatment visit on the 14th day of product use at which time blood
samples were obtained for TFV concentrations. Prior to the
application of the final study dose at the study site, participants
were randomized to collection of genital tract specimens at 4, 8 or
24 hours post-final dose on menstrual cycle day 19–24. As with the
single dose, blood samples were collected at all seven time points
[0.5, 1, 2, 4, 6, 8, and 24 hour(s)]. A post-treatment safety visit
occurred 1–2 weeks later, at which time the participant was
discontinued from the study if the examination was normal.
Because of the logistical difficulty of collecting samples at the 12-
hour time point, a substudy was performed at the University of
Pittsburgh site to enroll up to 10 women who had participated in
the main study to have biopsies and blood samples collected
12 hours after an additional single dose.
Twenty-one vaginal tissue samples from the single dose phase
were used for an interim analysis that was presented elsewhere and
is not reported here.
Sample Collection
The cervicovaginal fluid pooling in the posterior fornix was
aspirated with a 1.5 mL vaginal syringe, expelled into a cryogenic
vial, and frozen at 280uC. ECC specimens were collected with
two 360u turns of a cytobrush in the endocervix. The brush was
placed in a tube containing phosphate-buffered saline (PBS) and
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agitated to remove cells. The brush was removed, and the tube
was spun at 4uC at 400 relative centrifugal force (RCF)615 mi-
nutes. The pellet was resuspended in 1 mL PBS and a 10 ml
sample was mixed with 0.4% Trypan Blue and counted for
mononuclear cells. The remainder of the sample was spun at 4uC
at 400 RCF615 minutes and the cell pellet was mixed with
1.0 mL of ice cold 70% methanol, vortexed lightly to lyse the cells
and stored at 280uC.
The areas of the planned biopsies were gently wiped with a
small cotton swab moistened with warm saline followed by a small
cotton swab with betadine. Topical benzocaine gel was applied to
the areas of the planned biopsies for anesthesia. A medium-
Tischler biopsy forceps was used to obtain two 563 mm vaginal
biopsies; one from the upper one-third (proximal) and one from
the lower one-third (distal) of the vagina. Each biopsy was placed
in a pre-weighed individual vial and weighed, snap frozen in liquid
nitrogen, and stored at 280uC until transport. If adequate
hemostasis at a biopsy site was not obtained with pressure,
Monsel’s solution or silver nitrate was applied.
Drug Concentration Measurements
All methods were validated as mandated by the industry
guidance set by the US Department of Health and Human
Services (US DHHS), Food and Drug Administration (FDA),
Center for Drug Evaluation and Research (CDER).
Blood Plasma TFV Concentrations. Analysis of TFV was
performed by extracting drug species and internal standard from
200 mL standards, quality control samples, and participant
Figure 1. Study procedures.
doi:10.1371/journal.pone.0025974.g001
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samples using protein precipitation followed by a solid phase
extraction (SPE) procedure. A calibration curve for TFV ranged
from 0.5–200 ng/mL and utilized adefovir as the internal
standard. Across three quality control concentrations, intra-day
accuracy and precision was .99% and ,12%, respectively. Inter-
day accuracy and precision was .90% and ,13%, respectively.
The lower limit of quantification (LLOQ) for TFV was 0.5 ng/
mL. Detectable values below the limit of quantification (BLQ)
were imputed to be one-half of the LLOQ (0.25 ng/mL) and
values below the level of detection (BLD) were set to 0 ng/mL.
Cervical Vaginal Fluid (CVF) Concentrations. Analysis of
TFV in CVF was performed by extracting drug species and
internal standard from 50 mL standards, quality control samples,
and participant samples using protein precipitation with
acetonitrile containing 13C-labelled TFV internal standard. A
calibration curve for TFV ranged from 2–1,000 ng/mL. Intra-day
accuracy and precision was .93% and ,8%. Inter-day accuracy
and precision was .97% and ,5%.
TFV and TFV-DP Measurement in Vaginal Tissue. A
reverse-phase high performance liquid chromatography (RP-
HPLC) method employing tandem mass spectrometry detection
(LC-MS/MS) for the quantification of TFV and TFV-DP in
human vaginal tissue was performed by extracting drug species
from standards, quality control samples and participant samples
using tissue homogenization and a protein precipitation
procedure. An internal standard working solution of 13C-labelled
TFV and lamivudine triphosphate was used for the analysis of
TFV and TFV-DP, respectively. A calibration curve with a range
of 2–2,000 ng/mL for TFV, and 10–10,000 ng/mL for TFV-DP
was prepared from separate stock solutions. The LLOQ was 2 and
10 ng/mL for TFV and TFV-DP, respectively. The minimum
tissue sample weight required for this assay was 20 mg. Intra-day
accuracy and precision for TFV was .90% and ,10%,
respectively; for TFV-DP it was .94% and ,9%, respectively.
Inter-day accuracy and precision for TFV was .93% and ,5%,
respectively: for TFV-DP it was .98% and ,6% respectively. No
values at BLQ were imputed for the tissue data. Concentrations by
tissue weight (ng/g) were converted to volume (ng/mL) using a
vaginal tissue density of 1.01 g/mL. TFV-DP was also calculated
as fmol/0.2 mL based on the calculation that 0.2 mL is the
approximate volume equivalent of 106 mononuclear cells [9].
Endocervical Cells TFV-DP. Measurements of intracellular
TFV-DP concentrations in endocervical cells obtained by
cytobrush were performed as previously described in peripheral
blood mononuclear cells (PBMCs) [10,11].
Randomization
A random permuted blocks method was used to generate three
random allocation sequences by FHI. The first sequence was used to
randomize women to one of seven biopsy time points following
initial dosing of the gel, stratified by site. The second sequence was
used to randomize women to either once- or twice-daily dosing in
the 14-day follow-up period, stratified by site. The third sequence
was used to randomize women to one of the three concluding biopsy
time points, stratified by site and dosing arm within site. In order to
conceal the allocation procedure, random assignments were
contained within sequentially numbered, sealed opaque envelopes
which were maintained in a secure location at the sites and opened
by study staff at the time of randomization. The random sequences
were created using SAS (SAS Institute, Cary, NC).
Statistical Analysis
Study objectives were evaluated among participants enrolled
and randomized and who provided follow-up data. The primary
outcomes were local and systemic drug exposure of TFV after a
single dose and after 2 weeks of once- or twice-daily dosing. The
chosen sample size (49 women) was not based on formal power
considerations, but was deemed sufficient to characterize relevant
pharmacokinetic profiles, assuming groups of at least seven at each
time point and similar standard deviations as observed in previous
plasma data [5].
Blood plasma Cmax, Tmax and area under curve (AUC)0–24 h
(calculated using the linear trapezoidal method) were estimated by
noncompartmental analysis using WinNonlin Version 5.2 (Phar-
sight Corporation, Sunnyvale, CA). Because participants only
provided vaginal tissue specimens at a single time point in each
phase of the study, tissue TFV and TFV-DP Cmax and Tmax values
were estimated based on the median response at each time point
using SAS Version 9.1. For these sparse tissue data, the median
value at each time point was estimated and used to calculate Cmax
and Tmax. The composite of these median values was used to
calculate AUC0–24 h. Cervicovaginal fluid and cytobrush specimen
concentrations were summarized similarly.
Results
Recruitment for this study occurred from March 27, 2007 to
January 9, 2008. The last study visit was on April 11, 2008. A total
of 49 women met eligibility criteria and were enrolled (Figure 2).
All 49 women received a single dose of TFV gel in the clinic, but
two discontinued, one before and one after sample collection.
Therefore, 47 participants proceeded to the MD phase and were
randomized to once (QD) or twice daily (BID) dosing. Two of
these 47 participants discontinued prior to gel application. A total
of 975 doses were applied. Nine participants completed the 12-
hour substudy and used a total of nine doses.
Demographic characteristics for all enrolled participants are
shown in Table 1. Participants from the Dominican Republic
differed from the other two sites in that they more frequently
identified themselves as Hispanic and were less educated, and all
had a previous pregnancy and used female sterilization as their
birth control method (data not shown). Participants in Pittsburgh
had the highest mean Body Mass Index (34), those in Houston the
second highest (30), and those in the Dominican Republic the
lowest (28) (data not shown).
No deaths or Serious Adverse Events were reported. Of 192
Adverse Events (AEs) reported from 42 of 48 participants, 190
were reported during MD. The most frequently reported AEs
occurred within the following System Organ Class (SOC):
Reproductive System and Breast Disorder (27/48 participants,
56.3%), Nervous System Disorders (18/48 participants, 37.5%),
Gastrointestinal Disorders (18/48 participants, 37.5%), and
Investigations (13/48 participants, 27.1%).
Of the 192 reported AEs, 59 of these were designated as
possibly (n = 24), probably (n = 11) or definitely (n = 24) related to
the study gel or applicator and were experienced in 17
participants. Of the 59 designated as at least possibly related, 53
occurred in the Reproductive System and Breast Disorder SOC,
three occurred in the Gastrointestinal Disorder SOC and three
occurred in the Subcutaneous Tissue SOC.
A total of 8 severe AEs were reported by 6 women including
headaches (n = 4), vaginal hemorrhage (n = 2), subcutaneous
abscess (n = 1) and dysuria (n = 1), which were judged unrelated
to study product by site investigators.
A total of 26 moderate AEs were reported by 16 women. These
moderate AEs included dysmenorrhea (n = 4), headache (n= 4),
menorrhagia (n = 1), genital discomfort/pain (n = 2), back pain
(n = 2), vaginal odor (n = 1), hemoglobin decreased (n= 1), pruritus
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(n = 1), nasopharyngitis (n = 1), myalgia (n = 1), tonsillitis (n = 1),
toothache (n= 1), abdominal pain (n = 1), muscle spasm (n = 1),
arthralgia (n = 1), abdominal distention (n= 1), dysuria (n = 1) and
nausea (n = 1). Only three of these were judged to be related to
study product: vaginal odor, pruritus and vulvovaginal discomfort.
Table 2 shows the Reproductive System AEs reported in this
study. A total of 27 participants reported a total of 88
Reproductive System AEs. Of these, 5 participants reported 8
AEs of moderate severity [dysmenorrhea (4), menorrhagia (1),
vaginal odor (1), pruritus (1), vulvovaginal discomfort (1)], of which
the latter 3 were judged to be at least possibly related. Two
participants experienced bleeding from a biopsy site that required
immediate evaluation and treatment, which were judged as severe
but unrelated to study product. Of the remaining 78 Reproductive
System mild AEs, 50 were judged to be at least possibly product
related.
One participant became pregnant 3 weeks following exposure to
the single dose and was discontinued prior to the second phase.
The pregnancy ended in miscarriage, which was judged to be
unrelated to the study drug as it was remote from exposure. There
Figure 2. Participant flow diagram.
doi:10.1371/journal.pone.0025974.g002
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were no clinically significant changes in complete blood counts
and serum biochemistries between screening and the final visit
(data not shown).
Pharmacokinetic Parameters
TFV Plasma Measurement Data. The concentration of
TFV measured in all blood plasma samples ranged from below the
level of detection to 29.1 ng/mL. The median (interquartile range
[IQR]) estimate for Cmax in the single-dose phase was 4.0 ng/mL
(1.5–9.1) (Table 3). The median (IQR) estimate for Cmax at the
end of the 2-week phase was 3.4 ng/mL (2.4–6.1) when pooled
across dose groups (Table 4). The estimated Cmax was lower for
the once-daily group than for the twice-daily group: 2.5 ng/mL
(1.8–3.4) compared to 5.3 ng/mL (3.2–10.6) (Table S1). The
median AUC0–24 h was similar for the single- and multiple-dose
regimens: 36.4 ng * hr/mL (14.0–73.3) (Table 3) and 37.2 ng *
hr/mL (24.6–62.6) (Table 4), respectively. There were no
noticeable differences in exposure between SD and MD.
TFV Cervicovaginal Fluid Concentration. Pooling all
samples from 1 to 24 hours, the concentration of TFV in direct
aspiration of the cervicovaginal fluid ranged from 1.26104 to
9.96106 ng/mL.
The median Cmax after a single dose was 1.9610
6 ng/mL
(Table 3). The range was 1.2610429.96106.
The median Cmax at the end of the 2-week phase was
1.46106 ng/mL (Table 4). The range was 8.4610425.86106.
The median Cmax was similar for the once (QD) and twice daily
(BID) groups: 1.86106 ng/mL compared to 1.46106 ng/mL,
respectively (Table S1) and ranges of 8.4610422.46106 and
1.5610525.86106, respectively. The estimated AUC for the MD
QD and BID groups was 26.26106 and 18.46106, respectively
(Table S1).
TFV Vaginal Tissue. The data are presented in Table 3
which shows all data from SD, Table 4 which shows all data from
MD and Table S1 which compares SD and MD tissue
concentrations at equivalent time points for genital data (4, 8
and 24 hours).
TFV Vaginal Tissue [ng/mL]. There were 24 women who
contributed one time point [0.5, 1, 2, 4, 6, 8, or 24 hr(s)], 6 women
who contributed only to the 12 h time point and 3 who
contributed two time points ([0.5, 1, 2, 4, 6, 8, or 24 hr(s)] and
12 h) in the SD phase and 44 from the MD phase who contributed
tissue samples for TFV concentrations; all had detectable values.
One participant in the MD phase had a missing tissue sample, so
did not contribute to the analysis. To determine whether
systematic differences in TFV exposure could be detected, the
ratio of distal to proximal TFV concentration was calculated. The
geometric mean of this ratio did not differ significantly from 1
(0.91; 90% CI 0.78, 1.06). The values from the proximal and distal
vaginal specimens were averaged together for subsequent tissue
analysis, if both were available. Therefore, 36 data points
contributed to the SD analysis and 44 contributed to the MD
analysis.
Pooling all samples from 1 to 24 hours, the concentration of
TFV in the vaginal biopsies ranged from 2.16102 to 1.46106 ng/
mL.
The median Cmax was 2.2610
5 ng/mL after a single dose when
comparing all data points (Table 3) and 1.26104 estimated from 4,
8 and 24 hour samples (Table S1). The composite median AUC
for SD was 64.06104 and the C24 h was 0.7610
4 (Table 3).
The Cmax at the end of the 2-week phase was somewhat lower
for the once-daily than for the twice-daily group (2.96104 ng/mL
and 5.26104 ng/mL, respectively) (Table S1).
TFV-DP Vaginal Tissue [ng/mL]. Quantifiable TFV-DP
levels in vaginal tissue were detected in 15 out of 36 (42%) data
points that contributed to the SD phase analysis and 16 out of 44
(36%) in the MD phase analysis. Detectable concentrations in at
least one sample occurred in five out of 21 participants from the
Dominican Republic, 11 out of 14 from Houston and 8 out of 14
from Pittsburgh.
In those with detectable values, the vaginal biopsy concentrations
of TFV-DP ranged from 1.86102 to 3.56104 ng/mL. The median
Cmax after a single dose was 3.8610
3 ng/mL (1.76103 fmol/
0.2 mL) (Table 3), and at the end of the 2-week phase was
3.16103 ng/mL (1.36103 fmol/0.2 mL) (Table 4) in those with
Table 1. Participant characteristics.
Female (N=49)
N %
Age (years)
Mean 6 SD 33.8 (6.5)
Range 20–45
Ethnicity
Hispanic 26 53
Not Hispanic 23 47
Race
Black or African American 17 35
White 10 20
More than one race 22 45
Education (years)
Mean 6 SD 11.0 (3.9)
Body Mass Index
Mean 6 SD 30.3 (6.9)
Range 18–50
Ever pregnant
Yes 41 84
doi:10.1371/journal.pone.0025974.t001
Table 2. Reproductive system adverse events.
Tenofovir Gel (N=48)
# of events # of women (%)
Metrorrhagia/abnormal vaginal bleeding 16 12 (25)
Pruritus 28 9 (19)
Discharge 8 7 (15)
Vulvovaginal Discomfort 8 7 (15)
Dysmenorrhea 8 4 (8)
Vaginal Burning 4 4 (8)
Vaginal Odor 6 3 (6)
Genital Fissure 3 2 (4)
Vaginal Candidiasis 2 2 (4)
Bacterial Vaginosis 2 2 (4)
Menorrhagia 1 1 (2)
Vaginal Pain 2 1 (2)
Total 88 27 (56.3%)
doi:10.1371/journal.pone.0025974.t002
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detectable values. These latter Cmax median values were slightly
different for the once-daily and the twice-daily groups (1.16104 ng/
mL [4.76103 fmol/0.2 mL] compared to 0.36104 ng/mL
[1.26103 fmol/0.2 mL], respectively) (Table S1) with once-daily
concentrations higher at 8 hours and lower at 24 hours (Figure 3).
Intracellular TFV-DP in Endocervical Cells Collected by
Cytobrush. Quantifiable TFV-DP concentrations were
detectable in endocervical samples. After a single dose, the ECC
concentration of TFV-DP ranged from 7.16103 to 8.86106 ng/
mL and the median Cmax was 7.5610
5 ng/mL (3.46105 fmol/106
cells) (Table 3). The estimated Cmax at the end of the 2-week phase
was similar for the once-daily and the twice-daily groups
(4.26105 ng/mL compared to 4.46105 ng/mL, respectively)
(Table S1, Figure 3).
There was no evidence that the act of taking biopsy samples
influenced systemic blood TFV concentrations at later time points,
since concentrations were similar whether biopsies were taken
prior to or after the blood draw (data not shown).
Table S1 displays the median PK parameter estimates in the
various anatomical compartments comparing the 4, 8 and 24 hour
time points for single-dose and multiple-dose users. The AUC for
vaginal tissue TFV-DP was two logs higher in multiple-dose
compared to single-dose users but there were no noticeable
differences between QD and BID. In women with detectable
blood plasma concentrations, the median was close to zero at
24 hours. Vaginal tissue and endocervical cell TFV and TFV-DP
concentrations remained high at 24 hours. The changes in TFV
and TFV-DP concentrations in multiple compartments over the
24 hours following dose administration are shown in Figure 4.
Figure 4B represents only those values with measurable concen-
trations of TFV-DP.
Discussion
TFV gel is under development as a microbicide and is being
evaluated in clinical trials with pericoital and daily regimens. Due
to its long intracellular half-life, TFV disoproxil fumarate can be
taken once daily for oral treatment with tolerable side effects.
Extracellular and intracellular measurements of this compound
can be utilized to better assess required drug concentrations for
safety, efficacy, and the prevention of resistance through
pharmacokinetic studies. Measurements of extracellular TFV
have been performed in a number of matrices after oral exposure
and in blood after vaginal exposure [5]. Measurements of
intracellular concentrations of the active metabolite TFV-DP
have been performed in PBMCs [10]. We evaluated TFV
Table 3. Median single-dose (SD) PK parameters (all data points collected during the study).
Analyte, Matrix N
N
(.BLQ )
Samples
(.BLQ/Total #) Cmax (ng/mL) Tmax (hr)
AUC0–24 h (hr*ng/
mL) C24 h (ng/mL)
SD SD SD SD
TFV BP (IQR) 48 48 313/392 (80%) 4.0 (1.5–9.1) 4 (2–6) 36.4 (14.0–73.3) 0.3 (0.3–0.5)
TFV CVF 45 45 52/52 (100%) 1.96106 4 20.76106 0.16106
TFV Vaginal Tissue 33 333 72/72 (100%) 2.26105 2 64.06104 0.76104
TFV-DP ECC 48 39 42/57 (74%) 7.56105 4 47.46105 0.86105
TFV-DP Vaginal Tissue 33 154 36/72 (50%) 3.86103 1 12.46103 n/a
TFV-DP ECC1 48 39 42/57 (74%) 33.66104 4 212.26104 3.56104
TFV-DP Vaginal Tissue2 33 15 36/72 (50%) 1.76103 1 5.66103 n/a
1Cmax and C24 h in fmol/10
6 cells; AUC0–24 h in hr * fmol/10
6 cells.
2Cmax and C24 h in fmol/0.2 mL; AUC 0–24 h in hr * fmol/0.2 mL.
3Thirty-six data points contributed to the TFV tissue analysis.
4Fifteen data points out of a potential 36 contributed to the TFV-DP tissue analysis.
doi:10.1371/journal.pone.0025974.t003
Table 4. Median multi-dose (MD) PK parameters (all data points collected during the study).
Analyte, Matrix N
N
(.BLQ )
Samples (.BLQ/
Total #) Cmax (ng/mL) Tmax (hr)
AUC0–24 h (hr*ng/
mL) C24 h (ng/mL)
MD MD MD MD
TFV BP (IQR) 45 45 345/360 (96%) 3.4 (2.4–6.1) 4 (2–6) 37.2 (24.6–62.6) 0.3 (0.3–0.6)
TFV CVF 45 36 36/36 (100%) 1.46106 4 18.26106 0.66106
TFV Vaginal Tissue 45 45 89/89 (100%) 2.76104 4 34.56104 0.66104
TFV-DP ECC 45 35 35/45 (78%) 3.66105 8 44.56105 0.56105
TFV-DP Vaginal Tissue 45 16 24/89 (27%) 3.16103 8 43.46103 1.36103
TFV-DP ECC1 45 35 35/45 (78%) 16.26104 8 205.16104 3.16104
TFV-DP Vaginal Tissue2 45 16 24/89 (27%) 1.36103 8 19.46103 0.66103
1Cmax and C24 h in fmol/10
6 cells; AUC0–24 h in hr * fmol/10
6 cells.
2Cmax and C24 h in fmol/0.2 mL; AUC0–24 h in hr * fmol/0.2 mL.
doi:10.1371/journal.pone.0025974.t004
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concentrations in blood plasma, vaginal fluid and vaginal tissue
with single-dose administration as well as use over 14 consecutive
days. However, this is the first study to measure female genital
tissue and cell concentrations of TFV-DP, the active metabolite of
TFV gel. With topical microbicides, since the gel is administered
vaginally, it is important to measure intracellular concentrations in
addition to extracellular concentrations to be certain that TFV has
been absorbed.
With comparable sampling times (4, 8 and 24 hours), there was
a trend toward higher concentrations of both TFV and TFV-DP
in the vaginal tissue after multiple doses compared to a single dose,
and the AUC for vaginal tissue TFV-DP was two logs higher in
multiple-dose compared to single-dose users. Conversely, lower
concentrations of TFV-DP were observed in the endocervical cells
after multiple doses compared to a single dose. These and other
inconsistent patterns might be a result of variability within this
somewhat small sample and sparse data, making it hard to come to
definitive conclusions. However, the formation of more TFV-DP
after multiple doses is logical and would indicate that increased
exposure time and exposure to more TFV allows for greater
phosphorylation to occur within tissue mononuclear cells. Of
importance for either daily or pericoital dosing is the fact that TFV
tissue concentrations after both single and multiple doses were
above the range of in vitro anti-HIV-1 EC50s (0.4–8.5 mM) and
remained so for at least 24 hours post-dose [12,13]. Tenofovir
tissue concentrations were also above those required to inhibit
K65R-bearing viruses, a mutation that confers resistance to the
drug (EC50 = 25.3 mM) [14]. It is noteworthy, however, that
complete inhibition of HIV-1 replication in cervicovaginal tissues
may require tenofovir concentrations close to the median levels
achieved in mucosal tissues after gel administration. Given the
range of concentrations obtained after single and multiple doses of
tenofovir gel, it is conceivable that some women might not be fully
protected. Furthermore, environmental factors such as vaginal
infections or inflammation, which facilitate HIV infection, as well
as intercourse itself, may modify the required effective dose [15].
With multiple dosing, plasma TFV concentrations were about
twice as high after twice-daily compared to once-daily dosing.
There were no noticeable differences in TFV concentrations
between once- and twice-daily dosing in the cervicovaginal
aspirate. While the median concentration of TFV in vaginal tissue
was somewhat lower for the once-daily compared to the twice-
daily group, there were no noticeable increases in the concentra-
tions of the active metabolite (TFV-DP) in vaginal tissue or
endocervical cells when comparing once-daily to twice-daily use.
As expected with intravaginal dosing, the systemic exposure
after a single application was lower compared to that of oral
dosing. The AUC in plasma was 36.4 compared to approximately
103 ng * h/mL after an oral dose of TFV disoproxil fumarate as
reported by Hoetelmans, et al. [16]. In comparison, the
concentrations of TFV-DP in the genital tract were high at
exposures similar to, or up to 2 logs greater than what is seen in
PBMCs after oral administration [10], as shown in Figure 4B.
Ideally, a topical microbicide should have exactly these properties
of low systemic exposure and high local concentration in order to
minimize side effects and the development of resistance. The low
tenofovir plasma concentrations (1–30 nM) attained after intra-
vaginal gel administration are below its average in vitro EC50
(,1 mM), making the possibility of inducing resistant virus
unlikely. This assumption is further supported by the high genetic
barrier to resistance demonstrated by tenofovir, both in vitro and in
vivo [13,17].
Figure 3. Tenofovir-diphosphate (TFV-DP) median concentrations in endocervical cells (ECC) and vaginal tissue after once- or
twice-daily dosing.
doi:10.1371/journal.pone.0025974.g003
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Although high concentrations of intracellular TFV-DP were
detected in a subset of participants for at least 24 hours post-dose,
the window of protection afforded by vaginal application and the
target concentration of protection in tissue remains unknown.
However, concentrations in the cervicovaginal fluid were greater
than 104 ng/ml which has been suggested to be the required
threshold to prevent HIV infection based on Phase IIb data [18].
Without further study there is no way to know the ideal dosing
interval for pericoital application, as shorter or longer intervals
may be clinically effective.
Although our study is critical to the understanding of how TFV
gel is absorbed and metabolized in genital tissue, several
limitations must be acknowledged. Each participant only contrib-
uted to one time point for the vaginal biopsy due to feasibility
issues and the concern that conducting multiple biopsies in
individuals might affect plasma PK results. Because it did not
appear that biopsies led to increased systemic absorption, future
studies may consider conducting multiple biopsies in individuals to
obtain more complete PK profiles. Another limitation is that TFV-
DP was detectable in about 40% of the vaginal tissue biopsy
samples, and was detected less frequently at the Dominican
Republic site. The inability to detect TFV-DP in specimens was
likely due to the instability of the metabolite in tissue samples. This
issue was identified during the development of the analytical
method for TFV-DP whereby manipulation of the tissue quickly
degraded the TFV-DP to TFV. This phenomenon was verified by
two other laboratories, and has been subsequently overcome by
adding solvents such as methanol to inactivate the enzymes
responsible for this degradation. Finally, there is some evidence
that epithelial cells are able to phosphorylate TFV [19] and so the
tissue concentrations may be a reflection of phosphorylation by
both immune and epithelial cell populations. If so, the concen-
trations of TFV-DP reported in the cytobrush samples might be
artificially high because they were calculated from counts of
mononuclear cells in the sample, when a proportion of epithelial
cells were clearly present and potentially contributing to the
concentration measured. Similarly, the concentrations of TFV-DP
in the vaginal tissue might be falsely low, reflecting a dilution of the
sparse mononuclear cell population (,50,000 CD4+ cells/biopsy)
with epithelial cell concentrations. Epithelial cells may produce
TFV-DP at a different rate than immune cells, confounding the
interpretation of pharmacokinetic profiles. Nonetheless, the
concentrations of TFV-DP in genital tissue after vaginal dosing
appear to be higher than intracellular concentrations obtained in
PBMCs [10] and extracellular concentrations in vaginal fluid [20]
after oral dosing.
Our results show that single-dose and multiple-dose TFV gel
exposure leads to high genital tract concentrations for at least
24 hours post-dose and support further study of pericoital and
once-daily dosing of TFV gel as potential strategies for the
prevention of HIV transmission. The accurate determination of
the phosphorylated form of TFV in genital tissues adds to our
understanding of transmission pharmacokinetic-pharmacodynam-
ic relationships. These data also offer an understanding of the
genital tissue concentrations after single and multiple dosing that
may correlate with the reduction of HIV transmission that was
demonstrated in the recent Phase IIb study [8].
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